Atypical pharmacologies at beta-adrenoceptors.

about

Beta2-adrenoceptors and non-beta-adrenoceptors mediate effects of BRL37344 and clenbuterol on glucose uptake in soleus muscle: studies using knockout mice.GPCR theme editorial.

P2860

Q42943914-9BE6736E-E8E5-4F12-811D-EDB94420D083 Q42951309-9D320013-E94D-4F38-A1B1-0319D4F54099

P2860

Atypical pharmacologies at beta-adrenoceptors.

Item

http://www.wikidata.org/entity/Q36938463

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Atypical pharmacologies at beta-adrenoceptors.

@en

type

Item

label

Atypical pharmacologies at beta-adrenoceptors.

@en

prefLabel

Atypical pharmacologies at beta-adrenoceptors.

@en

P1476

Atypical pharmacologies at beta-adrenoceptors.

@en

P2093

R J Summers

http://www.w3.org/2001/XMLSchema#string

P2860

G protein-coupled receptor allosterism and complexing.

Characterization of the beta-adrenoceptor subtype involved in mediation of glucose transport in L6 cells.

Multiple signalling pathways involved in beta2-adrenoceptor-mediated glucose uptake in rat skeletal muscle cells.

Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors.

The low-affinity site of the beta1-adrenoceptor and its relevance to cardiovascular pharmacology.

Metabolic responses to BRL37344 and clenbuterol in soleus muscle and C2C12 cells via different atypical pharmacologies and beta2-adrenoceptor mechanisms

Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor.

Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy.

Biphasic effects of the beta-adrenoceptor agonist, BRL 37344, on glucose utilization in rat isolated skeletal muscle.

Ligand-directed signaling at the beta3-adrenoceptor produced by 3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate (SR59230A) relative to receptor agonists.

P304

285-287

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJP.2008.293

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

155

http://www.w3.org/2001/XMLSchema#string

P577

2008-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51415752

http://www.w3.org/2001/XMLSchema#string

P698

18641673

http://www.w3.org/2001/XMLSchema#string

P932

2567881

http://www.w3.org/2001/XMLSchema#string

Atypical pharmacologies at beta-adrenoceptors.

about

P2860

P2860

Atypical pharmacologies at beta-adrenoceptors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932